A Phase 2 interventional study of Belimumab and Placebo in Transplantation, Organ, sponsored by GlaxoSmithKline. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-25.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Kidney transplantation is the best treatment for many patients with kidney failure. Sometimes a transplanted kidney is rejected by the patient's immune system. Many types of immune system cells, including B cells, are active in rejection. B cells produce antibodies against anything the body sees as non-self, like germs or a transplanted kidney. Most medicines that help prevent transplant rejection affect cells other than B cells. Belimumab is a medication used to treat a disease called lupus. Belimumab slows development of antibody-producing B cells. This study will test whether belimumab works on parts of the immune system that cause rejection. Twenty to thirty adults getting a kidney transplant will be in this study. Like flipping a coin, a computer will randomly assign half to be given belimumab and half to be given placebo (a fake medicine). Patients and doctors will not know which medicine was assigned until the study is over. A total of 7 doses of study medicine will be given through a vein. One dose will be given during transplant surgery, and the other 6 will be given 2, 4, 8, 12, 16 and 20 weeks after transplant surgery. Usual transplant medicines will also be given. After all of the doses have been given, patients will be watched and tested at 24, 36, and 52 weeks after the transplant surgery. Blood samples will be tested to see what study medicines do to the immune system in transplant patients. If patients get a kidney biopsy, the samples will be tested to see if belimumab had any effect. Patients will be asked many questions to see if they are having any side effects. The study will be done at Addenbrooke's Hospital in Cambridge and Guys \&St Thomas Hospital in London, United Kingdom. A pharmaceutical company, GlaxoSmithKline, is funding the study.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 30 is below the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive belimumab 10 mg/ Kilogram (kg) infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care.
Drug: Belimumab
Subjects will receive placebo infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care
Drug: Placebo
Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
Change From Baseline in naïve B Cells From Baseline to Week 24
Naive B cell is cell that is not exposed to antigen. Naïve B cell count is CD20+CD27 concentration of cells (conc-cell)/cubic millimeter (cumm). Change from Baseline in naïve B cells was calculated as the value at Week 24 minus the value at Baseline. MITT Population consisted of all participants randomized to treatment, who have had taken at least one dose of study. Participants analyzed included those who had data at Week 24 for naïve B cells count (MITT Population). Baseline value used in the analysis was of Day 0 (Day of transplant). Adjusted mean differences (treatment-placebo) and 95% confidence intervals for differences were obtained from mixed-models repeated-measures (MMRM) model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments.
Time frame: Baseline and Week 24
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
Number of participants with AEs, SAEs and AESI are summarized. The On-treatment (OT) phase started on the day and time of receiving the start of the first infusion and ended on the last dose date plus 28 days. The Post-treatment (PT) phase started 29 days after day of last dose up to 1 year. An AE is any untoward medical occurrence, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in, death, is life threatening, Requires hospitalization or prolongation of existing hospitalization, Results in disability/incapacity, Is a congenital anomaly/birth defect or event that but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed. AESI included malignant neoplasms, infusion/anaphylaxis/hypersensitivity reactions, all infections, depression/suicide/self-injury, deaths.
Time frame: Up to 1 year
Number of Incidence of All Infections and Serious Infections
All infections included: 1. Opportunistic infections per-clinical assessment, 2. Herpes Zoster, a. Recurrent, b. Disseminated, 3. Sepsis. Opportunistic infections were identified using list of preferred terms as per Medical Dictionary for Regulatory Activities (MedDRA) version 18.1. Any events falling under these preferred terms were adjudicated to determine if criteria was met for an opportunistic infection.
Time frame: Up to 1 year
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24 and Week 52
Change from Baseline in SBP and DBP were assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Heart Rate From Baseline at Week 24 and Week 52
Change from Baseline in heart rate was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Body Temperature From Baseline at Week 24 and Week 52
Change from Baseline in body temperature was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Number of Participants Outside the Normal Range (NR) for SBP and DBP at Week 24 and Week 52
Number of participants outside the normal range (NR) for SBP and DBP was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Number of Participants Outside the Normal Range (NR) for Heart Rate at Week 24 and Week 52
Number of participants outside the normal range (NR) for heart rate was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Number of Participants Outside the Normal Range (NR) for Body Temperature at Week 24 and Week 52
Number of participants outside the normal range (NR) for body temperature was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Change From Baseline in the Indicated Hematology Parameters at Week 24 and Week 52
Hematology parameters included: basophils (B), eosinophils (E), lymphocytes (L), monocytes (M), total neutrophils (N), platelet count (PC) and white blood cells (WBC). Change from Baseline in haematology parameter was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in the Haematology Parameter- Hemoglobin at Week 24 and Week 52
Change from Baseline in hemoglobin was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in the Hematology Parameter- Hematocrit at Week 24 and Week 52
Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Haematology Parameter- Mean Corposcular Hemoglobin (MCH) at Week 24 and Week 52
Change from Baseline in MCH was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Haematology Parameter- Mean Corposcular Volume (MCV) at Week 24 and Week 52
Change from Baseline in MCV was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Haematology Parameter- Red Blood Cell (RBC) at Week 24 and Week 52
Change from Baseline in RBC was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Clinical Chemistry Parameter- Albumin at Week 24 and Week 52
Change from Baseline in albumin was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Clinical Chemistry Parameter- ALP, ALT, AST at Week 24 and Week 52
Clinical chemistry parameter included alkaline phosphatase (ALP), alanine amino Transferase (ALT) and aspartate amino transferase (AST). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Clinical Chemistry Parameter- Direct Bilirubin, Total Bilirubin and Creatinine at Week 24 and Week 52
Clinical chemistry parameters included direct bilirubin (DB), total bilirubin (TB) and creatinine (C). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Clinical Chemistry Parameter- Ca, CO2/Bicar, Gl, K, Na, PhI, U/BUN at Week 24 and Week 52
Clinical chemistry parameters included calcium (Ca), carbon dioxide content/bicarbonate (CO2/Bicar), glucose (Gl), potassium (K), sodium (Na), phosphorus inorganic (PhI), urea/blood urine nitrogen (U/BUN). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Clinical Chemistry Parameter- Glomerular Filtration Rate (GFR) at Week 24 and Week 52
Change from Baseline in GFR was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 24 and Week 52
Change from Baseline in immunoglobulins IgA, IgG and IgM was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24 and Week 52
Median Percent Change From Baseline in Memory B Cell Count at Week 24 and Week 52
Memory B cells are B cell sub-type that are formed within germinal centres following primary infection and are important in generating an accelerated and more robust antibody-mediated immune response in the case of re-infection. Memory B cell count included CD20+CD27+ cells/mm\^3. Baseline value used in the analysis was of Day 0 (Day of transplant). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Percent change from Baseline in Memory B cell count was calculated as the value at Week 24 and Week 52 minus the value at Baseline multiplied by 100. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Median Difference and 95% confidence interval of difference obtained using the Hodges-Lehmann method.
Time frame: Baseline, Week 24 and Week 52
Activated Memory B Cells Count at Week 24 and Week 52
Activated memory B cell-CD95% count is CD19+CD27+CD95 conc-cells/mL. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Activated Memory B Cells Percentage at Week 24 and Week 52
Activated memory B cell-CD95% percentage is CD19+CD27+CD95+ (%CD19/CD27). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Transitional B Cells Count at Week 24 and Week 52
Transitional B cell count (Newell) is CD19+CD24b+CD38b+IgD+ (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Transitional B Cells Percentage at Week 24 and Week 52
Transitional B cell percentage (Newell) is CD19+CD24b+CD38b+IgD+ (%CD19+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Activated T Cell Count at Week 24 and Week 52
A T cell is a type of lymphocyte that plays a central role in cell-mediated immunity. Activated T cell count Codarri is CD4+ CD25hi CD45RA- IL 7Rhi (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Activated T Cell Percentage at Week 24 and Week 52
Activated T cell percentage (Codarri)= CD4+ CD25hi CD45RA- IL 7Rhi (% of CD4+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Regulatory T Cell Count at Week 24 and Week 52
Regulatory T cell count is CD4+ CD25hi IL-7Rlo (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Regulatory T Cell (%CD4) at Week 24 and Week 52
Regulatory T cell (%CD4) = CD4+ CD25hi IL-7Rlo (% of CD4+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Mean Activated: Regulatory T Cell Ratio at Week 24 and Week 52
Activated: regulatory T cell ratio is Activated T cell CD4+CD25hi CD45RA IL 7Rhi (absolute number)/ Regulatory T cell CD4+CD25hi CD45RA IL 7Rlo (absolute number). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Proportion of Participants With Episodes of Acute Rejection at Week 24 and Week 52
The endpoint diagnosis was made by a proven biopsy result. Number of rejections only counted once per participant. The proportion of participants with episodes of acute rejection was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Mean Serum Creatinine at Week 24 and Week 52
Adjusted mean difference for serum creatinine values (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction, at Week 24 and Week 52. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24 and Week 52
Mean eGFR at Week 24 and Week 52
The estimated glomerular filtration rate (eGFR) were calculated by the abbreviated Modification of Diet in Renal Disease (MDRD) equation. Adjusted mean difference(treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction at Week 24 and Week 52. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the indicated time points were analyzed (represented by n= X, X in the category titles).
Time frame: Week 24 and Week 52
Mean Prednisolone Use at Week 24
Adjusted mean difference (treatment-placebo) for Prednisolone use and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction at Week 24. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments Only those participants available at indicated timepoints were analyzed (represented by n=X, X in the category titles).
Time frame: Week 24
A total of 30 renal transplant recipients were enrolled, of which 28 were randomized and 25 were transplanted.
| Milestone | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Started | 13 | 12 |
| Completed | 11 | 9 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Naive B cell is cell that is not exposed to antigen. Naïve B cell count is CD20+CD27 concentration of cells (conc-cell)/cubic millimeter (cumm). Change from Baseline in naïve B cells was calculated as the value at Week 24 minus the value at Baseline. MITT Population consisted of all participants randomized to treatment, who have had taken at least one dose of study. Participants analyzed included those who had data at Week 24 for naïve B cells count (MITT Population). Baseline value used in the analysis was of Day 0 (Day of transplant). Adjusted mean differences (treatment-placebo) and 95% confidence intervals for differences were obtained from mixed-models repeated-measures (MMRM) model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments.
| cells/mm^3 | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Change From Baseline in naïve B Cells From Baseline to Week 24 | 4.0 ± 25.55 | -30.4 ± 27.50 |
Number of participants with AEs, SAEs and AESI are summarized. The On-treatment (OT) phase started on the day and time of receiving the start of the first infusion and ended on the last dose date plus 28 days. The Post-treatment (PT) phase started 29 days after day of last dose up to 1 year. An AE is any untoward medical occurrence, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in, death, is life threatening, Requires hospitalization or prolongation of existing hospitalization, Results in disability/incapacity, Is a congenital anomaly/birth defect or event that but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed. AESI included malignant neoplasms, infusion/anaphylaxis/hypersensitivity reactions, all infections, depression/suicide/self-injury, deaths.
| Participants | Placebo | Belimumab 10mg/kg |
|---|---|---|
| OT AEs | 10 | 11 |
| PT AEs | 9 | 10 |
| OT SAEs | 7 | 5 |
| PT SAEs | 2 | 2 |
| Malignant neoplasms | 0 | 0 |
| Post-Infusion Systemic Reactions | 0 | 1 |
| All Infections | 6 | 7 |
| Depression/suicide/self-injury | 0 | 0 |
| Deaths | 1 | 0 |
All infections included: 1. Opportunistic infections per-clinical assessment, 2. Herpes Zoster, a. Recurrent, b. Disseminated, 3. Sepsis. Opportunistic infections were identified using list of preferred terms as per Medical Dictionary for Regulatory Activities (MedDRA) version 18.1. Any events falling under these preferred terms were adjudicated to determine if criteria was met for an opportunistic infection.
| Infections | Placebo | Belimumab 10mg/kg |
|---|---|---|
| All Infections | 8 | 7 |
| Serious Infections | 2 | 1 |
| All Opportunistic Infections | 7 | 5 |
| Serious Opportunistic Infections | 1 | 0 |
| All Herpes Zoster | 0 | 1 |
| Serious Herpes Zoster | 0 | 0 |
| Sepsis | 3 | 2 |
| Serious Sepsis | 2 | 1 |
Change from Baseline in SBP and DBP were assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| millimeter of mercury (mmHg) | Placebo | Belimumab 10mg/kg |
|---|---|---|
| DBP Week 24; n=9, 7 | -4.444 ± 14.3275 | 7.286 ± 13.8289 |
| DBP Week 52; n=11, 10 | -6.545 ± 13.9668 | 4.200 ± 8.5479 |
| SBP Week 24; n=9, 7 | 2.000 ± 26.0960 | 10.000 ± 35.9444 |
| SBP Week 52; n=11, 10 | -2.909 ± 27.2046 | 3.300 ± 27.9008 |
Change from Baseline in heart rate was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Beats per minute (BPM) | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=8, 6 | 5.125 ± 16.8983 | 1.500 ± 13.6345 |
| Week 52; n=11, 9 | 2.000 ± 11.5065 | -2.444 ± 15.4200 |
Change from Baseline in body temperature was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value at Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Degree Centigrade | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=8, 6 | 0.025 ± 0.7025 | -0.233 ± 0.5007 |
| Week 52; n=11, 10 | -0.045 ± 0.4803 | 0.030 ± 0.5417 |
Number of participants outside the normal range (NR) for SBP and DBP was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Participants | Placebo | Belimumab 10mg/kg |
|---|---|---|
| DBP, > NR, Week 24; n=9, 7 | 1 | 1 |
| DBP, < NR, Week 24; n=9, 7 | 1 | 2 |
| DBP, > NR, Week 52; n=11, 10 | 3 | 0 |
| DBP, < NR, Week 52; n=11, 10 | 2 | 1 |
| SBP, > NR, Week 24; n=9, 7 | 5 | 3 |
| SBP, < NR, Week 24; n=9, 7 | 0 | 0 |
| SBP, > NR, Week 52; n=11, 10 | 5 | 4 |
| SBP, < NR, Week 52; n=11, 10 | 0 | 1 |
Number of participants outside the normal range (NR) for heart rate was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Participants | Placebo | Belimumab 10mg/kg |
|---|---|---|
| > NR Week 24; n=8, 6 | 1 | 0 |
| < NR Week 24; n=8, 6 | 2 | 0 |
| > NR Week 52; n=11, 9 | 0 | 0 |
| < NR Week 52; n=11, 9 | 1 | 1 |
Number of participants outside the normal range (NR) for body temperature was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Number of participants outside the normal range are summarized by less than (\<) normal range and greater than (\>) normal range categories at Week 24 and Week 52. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Participants | Placebo | Belimumab 10mg/kg |
|---|---|---|
| > NR Week 24; n=8, 6 | 0 | 0 |
| < NR Week 24; n=8, 6 | 3 | 4 |
| > NR Week 52; n=11, 10 | 0 | 0 |
| < NR Week 52; n=11, 10 | 5 | 2 |
Hematology parameters included: basophils (B), eosinophils (E), lymphocytes (L), monocytes (M), total neutrophils (N), platelet count (PC) and white blood cells (WBC). Change from Baseline in haematology parameter was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Gills/Liter (GI/L) | Placebo | Belimumab 10mg/kg |
|---|---|---|
| B Week 24; n=9, 6 | -0.001 ± 0.0215 | -0.015 ± 0.0207 |
| B Week 52; n=10, 10 | 0.033 ± 0.1024 | -0.005 ± 0.0357 |
| E Week 24; n=9, 6 | -0.531 ± 1.0250 | -0.140 ± 0.1274 |
| E Week 52; n=10, 10 | -0.392 ± 0.8048 | -0.127 ± 0.1489 |
| L Week 24; n=9, 6 | -0.218 ± 0.6457 | -0.347 ± 0.3467 |
| L Week 52; n=10, 10 | 0.085 ± 0.5841 | -0.245 ± 0.3357 |
| M Week 24; n=9, 6 | -0.097 ± 0.2231 | -0.365 ± 0.3509 |
| M Week 52; n=10, 10 | 0.001 ± 0.1799 | -0.111 ± 0.3892 |
| TN Week 24; n=9, 6 | 0.946 ± 2.6602 | -0.083 ± 2.4752 |
| TN Week 52; n=10, 10 | 1.657 ± 3.5533 | -0.606 ± 3.3406 |
| PC Week 24; n=9, 6 | 15.9 ± 59.64 | 7.3 ± 40.35 |
| PC Week 52; n=11, 10 | 18.1 ± 55.81 | -10.0 ± 54.14 |
| WBC Week 24; n=9, 6 | 0.10 ± 3.483 | -0.95 ± 2.868 |
| WBC Week 52; n=11, 10 | 1.47 ± 3.572 | -1.11 ± 3.557 |
Change from Baseline in hemoglobin was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Grams per Liter (G/L) | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 6 | 5.4 ± 24.84 | 13.2 ± 28.90 |
| Week 52; n=11, 10 | 12.6 ± 22.69 | 6.3 ± 23.48 |
Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Percentage of blood | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 6 | 0.0216 ± 0.06625 | 0.0477 ± 0.09540 |
| Week 52; n=11, 10 | 0.0434 ± 0.06813 | 0.0238 ± 0.07045 |
Change from Baseline in MCH was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Picogram (pg) | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=8, 6 | -0.79 ± 2.173 | -1.37 ± 2.683 |
| Week 52; n=10, 10 | -1.59 ± 1.516 | -1.93 ± 2.743 |
Change from Baseline in MCV was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Femtoliter (FL) | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 6 | -1.73 ± 6.430 | -2.55 ± 8.198 |
| Week 52; n=11, 10 | -3.58 ± 4.340 | -4.61 ± 7.041 |
Change from Baseline in RBC was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Tera (TI)/L | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 6 | 0.298 ± 0.6716 | 0.645 ± 0.8097 |
| Week 52; n=11, 10 | 0.635 ± 0.7064 | 0.468 ± 0.5884 |
Change from Baseline in albumin was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| G/L | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 7 | 4.1 ± 2.62 | 2.9 ± 4.91 |
| Week 52; n=10, 10 | 2.9 ± 3.00 | 1.8 ± 4.98 |
Clinical chemistry parameter included alkaline phosphatase (ALP), alanine amino Transferase (ALT) and aspartate amino transferase (AST). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| International Unit (IU)/L | Placebo | Belimumab 10mg/kg |
|---|---|---|
| ALP Week 24; n=9, 7 | -16.0 ± 26.14 | -5.0 ± 60.03 |
| ALP Week 52; n=10, 10 | -17.5 ± 35.25 | 19.9 ± 80.63 |
| ALT Week 24; n=9, 7 | 1.0 ± 15.86 | 5.1 ± 7.56 |
| ALT Week 52; n=10, 10 | -2.5 ± 11.16 | 2.1 ± 5.80 |
| AST Week 24; n=6, 3 | 3.2 ± 7.91 | 7.3 ± 4.04 |
| AST Week 52; n=7, 4 | 3.3 ± 5.68 | 9.3 ± 3.86 |
Clinical chemistry parameters included direct bilirubin (DB), total bilirubin (TB) and creatinine (C). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Micromole per Liter (umol/L) | Placebo | Belimumab 10mg/kg |
|---|---|---|
| DB Week 24; n=8, 3 | 0.6 ± 1.51 | -0.7 ± 3.06 |
| DB Week 52; n=9, 5 | 0.9 ± 1.54 | 0.2 ± 1.30 |
| TB Week 24; n=9, 7 | 3.0 ± 6.50 | 2.7 ± 5.22 |
| TB Week 52; n=10, 10 | 2.9 ± 5.26 | 2.9 ± 3.38 |
| C Week 24; n=9, 7 | -471.1 ± 317.54 | -571.3 ± 183.53 |
| C Week 52; n=10, 10 | -468.4 ± 310.54 | -609.8 ± 271.89 |
Clinical chemistry parameters included calcium (Ca), carbon dioxide content/bicarbonate (CO2/Bicar), glucose (Gl), potassium (K), sodium (Na), phosphorus inorganic (PhI), urea/blood urine nitrogen (U/BUN). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Millimole (MMOL)/L | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Ca Week 24; n=9, 7 | 0.116 ± 0.1344 | 0.167 ± 0.1942 |
| Ca Week 52; n=10, 9 | 0.116 ± 0.1013 | 0.128 ± 0.1386 |
| CO2/Bicar Week 24; n=7, 6 | -3.73 ± 5.951 | 1.70 ± 3.449 |
| CO2/Bicar Week 52; n=8, 9 | -2.68 ± 5.142 | 0.77 ± 3.588 |
| Gl Week 24; n=5, 5 | 0.20 ± 3.093 | -0.04 ± 2.003 |
| Gl Week 52; n=5, 8 | -0.32 ± 2.483 | 1.79 ± 4.107 |
| K Week 24; n=9, 7 | 0.06 ± 0.723 | -0.63 ± 0.923 |
| K Week 52; n=10, 10 | -0.02 ± 0.535 | -0.44 ± 0.877 |
| Na Week 24; n=9, 7 | -0.6 ± 4.03 | 5.9 ± 5.01 |
| Na Week 52; n=10, 10 | -0.7 ± 3.71 | 2.2 ± 4.71 |
| PhI Week 24; n=8, 7 | -0.225 ± 0.3843 | -0.913 ± 0.5862 |
| PhI Week 52; n=9, 9 | -0.227 ± 0.4234 | -0.726 ± 0.5453 |
| U/BUN Week 24; n=9, 6 | -5.91 ± 12.164 | -9.47 ± 9.128 |
| U/BUN Week 52; n=10, 9 | -8.13 ± 14.967 | -9.01 ± 7.323 |
Change from Baseline in GFR was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| milliliter (mL)/Minute (min) | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 7 | 42.80 ± 23.604 | 44.36 ± 10.731 |
| Week 52; n=10, 10 | 42.33 ± 29.140 | 53.75 ± 15.176 |
Change from Baseline in immunoglobulins IgA, IgG and IgM was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Change from Baseline was calculated as the value on Week 24 and Week 52 minus the value at Baseline. Baseline value used in the analysis was of Day 0 (Day of transplant). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| G/L | Placebo | Belimumab 10mg/kg |
|---|---|---|
| IgA Week 24; n=2, 3 | -0.500 ± 0.2828 | -0.433 ± 0.6429 |
| IgA Week 52; n=2, 3 | -0.300 ± 0.0000 | -0.500 ± 0.5292 |
| IgG Week 24; n=6, 6 | -1.02 ± 1.184 | -2.40 ± 1.731 |
| IgG Week 52; n=10, 9 | 0.78 ± 3.595 | -2.13 ± 1.702 |
| IgM Week 24; n=2, 3 | -0.100 ± 0.0000 | -0.133 ± 0.3512 |
| IgM Week 52; n=2, 3 | 0.0000 ± 0.0000 | -0.333 ± 0.4933 |
Memory B cells are B cell sub-type that are formed within germinal centres following primary infection and are important in generating an accelerated and more robust antibody-mediated immune response in the case of re-infection. Memory B cell count included CD20+CD27+ cells/mm\^3. Baseline value used in the analysis was of Day 0 (Day of transplant). Endpoint was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Percent change from Baseline in Memory B cell count was calculated as the value at Week 24 and Week 52 minus the value at Baseline multiplied by 100. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Median Difference and 95% confidence interval of difference obtained using the Hodges-Lehmann method.
| Percent change | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 7 | -12.5 (-88 to 320) | 177.8 (40 to 800) |
| Week 52; n=10, 7 | 2.4 (-67 to 340) | -33.3 (-80 to 44) |
Activated memory B cell-CD95% count is CD19+CD27+CD95 conc-cells/mL. Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| cells/mL | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 7 | 37157.2 ± 16664.42 | 38389.6 ± 18682.83 |
| Week 52; n=10, 8 | 24220.8 ± 15744.17 | 11092.5 ± 17711.36 |
Activated memory B cell-CD95% percentage is CD19+CD27+CD95+ (%CD19/CD27). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Percentage of activated memory B cells | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 7 | 32.8 ± 5.94 | 19.0 ± 6.06 |
| Week 52; n=11, 10 | 32.0 ± 5.07 | 38.8 ± 5.48 |
Transitional B cell count (Newell) is CD19+CD24b+CD38b+IgD+ (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| cells/mL | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 7 | 5470 ± 2910.9 | 2679 ± 3518.4 |
| Week 52; n=10, 8 | 7110 ± 2836.7 | 6652 ± 3291.5 |
Transitional B cell percentage (Newell) is CD19+CD24b+CD38b+IgD+ (%CD19+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Percentage of transitional B cells | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 7 | 2.43 ± 0.776 | 1.14 ± 0.869 |
| Week 52; n=11, 10 | 2.61 ± 0.713 | 3.41 ± 0.731 |
A T cell is a type of lymphocyte that plays a central role in cell-mediated immunity. Activated T cell count Codarri is CD4+ CD25hi CD45RA- IL 7Rhi (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| cells/mL | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 6 | 109279.5 ± 22998.02 | 78952.7 ± 26155.19 |
| Week 52; n=10, 7 | 122304.7 ± 21898.24 | 75349.4 ± 24313.62 |
Activated T cell percentage (Codarri)= CD4+ CD25hi CD45RA- IL 7Rhi (% of CD4+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Percentage of activated T cell | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 6 | 17.0 ± 2.29 | 14.0 ± 2.58 |
| Week 52; n=10, 7 | 15.2 ± 2.15 | 14.7 ± 2.33 |
Regulatory T cell count is CD4+ CD25hi IL-7Rlo (Conc-cells/mL). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| cells/mL | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n= 9, 7 | 23586.2 ± 8427.77 | 24234.5 ± 9238.41 |
| Week 52; n= 10, 8 | 33038.7 ± 7676.99 | 27419.8 ± 9093.84 |
Regulatory T cell (%CD4) = CD4+ CD25hi IL-7Rlo (% of CD4+). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Percentage of Regulatory T cell | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n= 9, 7 | 4.4 ± 1.12 | 4.6 ± 1.25 |
| Week 52; n= 11, 10 | 5.0 ± 1.01 | 4.4 ± 1.04 |
Activated: regulatory T cell ratio is Activated T cell CD4+CD25hi CD45RA IL 7Rhi (absolute number)/ Regulatory T cell CD4+CD25hi CD45RA IL 7Rlo (absolute number). Adjusted mean difference (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Ratio | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n= 9, 6 | 4.88 ± 0.832 | 3.33 ± 0.915 |
| Week 52; n= 10, 7 | 4.62 ± 0.779 | 3.61 ± 0.942 |
The endpoint diagnosis was made by a proven biopsy result. Number of rejections only counted once per participant. The proportion of participants with episodes of acute rejection was assessed at Week 24 (at the end of therapy) and at Week 52 (at study end). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Proportion of participants | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=5, 6 | 0.4 | 0.33 |
| Week 52; n=5, 6 | 0.6 | 0.33 |
Adjusted mean difference for serum creatinine values (treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction, at Week 24 and Week 52. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| micromole/L | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 7 | 115.1 ± 35.24 | 112.3 ± 38.20 |
| Week 52; n= 10, 10 | 135.4 ± 33.50 | 122.6 ± 33.37 |
The estimated glomerular filtration rate (eGFR) were calculated by the abbreviated Modification of Diet in Renal Disease (MDRD) equation. Adjusted mean difference(treatment-placebo) and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction at Week 24 and Week 52. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments. Only those participants available at the indicated time points were analyzed (represented by n= X, X in the category titles).
| mL/minute/1.73 square meter (m^2) | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Week 24; n=9, 7 | 62.25 ± 6.119 | 49.33 ± 6.897 |
| Week 52; n= 10, 10 | 58.99 ± 5.732 | 56.29 ± 5.765 |
Adjusted mean difference (treatment-placebo) for Prednisolone use and 95% confidence intervals for differences were obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and treatment-by-visit interaction and fixed continuous covariates of Baseline and Baseline-by-visit interaction at Week 24. A compound symmetry variance structure was used to model the within-participant errors, shared across treatments Only those participants available at indicated timepoints were analyzed (represented by n=X, X in the category titles).
| mg/day | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Mean Prednisolone Use at Week 24 | 5.71 ± 1.438 | 5.27 ± 1.713 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to 52 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 7/13 (53.8%) | 9/13 (69.2%) |
| Belimumab 10mg/kg | — | 5/12 (41.7%) | 9/12 (75%) |
| Event | Placebo | Belimumab 10mg/kg |
|---|---|---|
| Blood creatinine increasedInvestigations | 0/13 | 1/12 |
| Clostridium difficile colitisInfections and infestations | 0/13 | 1/12 |
| ColitisGastrointestinal disorders | 0/13 | 1/12 |
| DehydrationMetabolism and nutrition disorders | 0/13 | 1/12 |
| DeliriumPsychiatric disorders | 0/13 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 0/13 | 1/12 |
| Focal segmental glomerulosclerosisRenal and urinary disorders | 0/13 | 1/12 |
| LymphoceleVascular disorders | 0/13 | 1/12 |
| PneumoniaInfections and infestations | 0/13 | 1/12 |
| Transplant rejectionImmune system disorders | 0/13 | 1/12 |
| Event | Placebo | Belimumab 10mg/kg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/13 | 5/12 |
| LeukopeniaBlood and lymphatic system disorders | 4/13 | 4/12 |
| Urinary tract infectionInfections and infestations | 2/13 | 4/12 |
| AnaemiaBlood and lymphatic system disorders | 3/13 | 2/12 |
| DyspepsiaGastrointestinal disorders | 2/13 | 2/12 |
| Alanine aminotransferase increasedInvestigations | 1/13 | 2/12 |
| Lower respiratory tract infectionInfections and infestations | 1/13 | 2/12 |
| DizzinessNervous system disorders | 0/13 | 2/12 |
| VomitingGastrointestinal disorders | 0/13 | 2/12 |
| NasopharyngitisInfections and infestations | 2/13 | 1/12 |
| Age, Continuous(Years) | Placebo | Belimumab 10mg/kg | Total |
|---|---|---|---|
| Mean | 51.0 ± 14.02 | 54.3 ± 11.02 | 52.6 ± 12.52 |
| Sex: Female, Male(Participants) | Placebo | Belimumab 10mg/kg | Total |
|---|---|---|---|
| Female | 4 | 7 | 11 |
| Male | 9 | 5 | 14 |
| Race/Ethnicity, Customized(Participants) | Placebo | Belimumab 10mg/kg | Total |
|---|---|---|---|
| White/Caucasian | 12 | 11 | 23 |
| Asian | 1 | 1 | 2 |
The record gives a start of Sep 2013, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab